Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir

Antiviral Res. 2003 May;58(3):209-15. doi: 10.1016/s0166-3542(02)00214-0.

Abstract

Lactoferrin (LF) is a multifunctional glycoprotein, which plays an important role in immune regulation and defense mechanisms against bacteria, fungi, and viruses. Upon peptic digestion of LF, a peptide called lactoferricin (Lfcin) is generated. Lfcin corresponds to the N-terminal part of the protein. In this study we investigated the antiviral activity of bovine and human Lfcin against Herpes simplex virus (HSV)-1 and HSV-2. The 50% effective concentrations (EC(50)) for LF and Lfcin against several clinical isolates of HSV-1 and HSV-2, including acyclovir (ACV)-resistant strains, were determined. We further evaluated the effect of the combination of either LF or Lfcin with ACV against HSV-1 and HSV-2. Synergy was observed between both LF or Lfcin in combination with ACV against the HSV laboratory strains. The 50% effective concentration (EC(50)) for ACV and LF or Lfcin, when combined with ACV, could be reduced by two- to sevenfold compared to the EC(50) when the drugs were used alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / pharmacology*
  • Animals
  • Antiviral Agents / pharmacology*
  • Cattle
  • Chlorocebus aethiops
  • Drug Resistance, Viral
  • Drug Synergism
  • Herpesvirus 1, Human / drug effects*
  • Herpesvirus 2, Human / drug effects*
  • Humans
  • Lactoferrin / analogs & derivatives*
  • Lactoferrin / pharmacology*
  • Microbial Sensitivity Tests
  • Vero Cells
  • Viral Plaque Assay

Substances

  • Antiviral Agents
  • lactoferricin B
  • Lactoferrin
  • Acyclovir